> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rezolute Finishes Enrolling 16-Patient Tumor Hyperinsulinism Trial, Expects Topline Data Mid-December
- URL: https://www.bullished.co/rezolute-finishes-enrolling-16-patient-tumor-hyperinsulinism-trial-expects-topline-data-5dc3335f/
- Published: 2026-10-14T21:21:53.000Z
- Updated: 2026-10-28T21:33:07.000Z
- Description: The ersodetug trial needs a response rate of at least 56% among 16 participants to clear its statistical bar.
- Author: Matteo Parrino
- Tags: SEC Filings, RZLT, Industry: Healthcare

[Rezolute](https://www.bullished.co/tag/rzlt/) said in an [8-K filed Wednesday](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926115874/tm2627620d1%5F8k.htm?ref=bullished.co) that its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is [fully enrolled](https://rss.globenewswire.com/news-release/2026/10/14/3381134/0/en/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism.html?ref=bullished.co), with topline results expected in mid-December 2026\. The trial covers 16 participants, and success hinges on a [response rate of at least 56%](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926115874/tm2627620d1%5Fex99-1.htm?ref=bullished.co).

## What the press release says

upLIFT is a single-arm, open-label, registrational study, meaning every participant gets the drug and the study is designed to support a regulatory filing. It enrolls people with insulinoma or non-islet cell tumors who have uncontrolled low blood sugar caused by tumor hyperinsulinism.

Participants who need continuous intravenous glucose receive ersodetug at 9 mg/kg per week for 8 weeks, added to standard care. After that, all participants may continue in long-term extension.

The main goal is the share of participants who cut their glucose infusion rate by at least 50% from baseline within the 8-week phase. For statistical significance, the lower bound of the 95% confidence interval for the responder rate must be at least 30%. The company said that [equates to](https://rss.globenewswire.com/news-release/2026/10/14/3381134/0/en/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism.html?ref=bullished.co) a response rate of at least 56% (a 95% confidence interval of 30-80%) for 16 participants.

Additional endpoints include how many participants stop glucose infusion entirely and how long that takes, time to hospital discharge, hypoglycemia events and time, and patient-reported quality of life.

## What the earlier data showed

Earlier this year, the company announced that 7 of the 8 participants enrolled in the first half of the study met the responder criterion. Each of those seven also stopped intravenous glucose completely on ersodetug, and the company said the drug has been well tolerated so far, with no drug-related safety findings.

The eighth participant chose hospice care at home shortly after enrollment and died one week later from cancer progression. Rezolute counts that person as a non-responder for the primary endpoint.

## What it changes

The release sets a timeline: topline data in mid-December 2026\. Rezolute also plans to keep its expanded access program running, supplying ersodetug on a compassionate-use basis to people with serious, refractory hypoglycemia from tumor hyperinsulinism.

Chief Medical Officer Dr. Brian Roberts said that, "to the extent the study outcomes are favorable," the company sees "the potential to advance both indications in 2027," referring to tumor and congenital hyperinsulinism. The release cautions that even a successful study offers no assurance regulators will approve ersodetug for either condition, and that ersodetug for hyperinsulinism remains investigational.

Rezolute shares closed at $4.23 on Wednesday and traded at $4.27 in Wednesday after-hours trading, a reading taken before the 5:11 p.m. ET filing.

The next date that matters is mid-December 2026, when upLIFT topline data are due.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Rezolute, Inc. (RZLT)](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926115874/tm2627620d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2627620d1\_ex99-1.htm — Rezolute, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926115874/tm2627620d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Rezolute Announces Completion of Enrollment in Phase 3](https://rss.globenewswire.com/news-release/2026/10/14/3381134/0/en/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism.html?ref=bullished.co) — rss.globenewswire.com

### More on Rezolute

- [Jennison Associates Takes A 5.5% Passive Stake In Rezolute, Holding 5.3 Million Shares](https://www.bullished.co/jennison-associates-takes-a-5-5-passive-stake-in-rezolute-holding-5-3-million-shares-2ac28d6a/)
- [Rezolute's CEO Took Home $5,711,410 And Also Chairs The Board, Proxy Shows](https://www.bullished.co/rezolutes-ceo-took-home-5-711-410-and-also-chairs-the-board-proxy-shows-61925309/)
- [FDA Tells Rezolute To Request Pre-BLA Meeting On Ersodetug, But Won't Say If It's Approvable](https://www.bullished.co/fda-tells-rezolute-to-request-pre-bla-meeting-on-ersodetug-but-wont-say-if-its-approvable-4fe49f0c/)

[All Rezolute (RZLT) coverage →](https://www.bullished.co/tag/rzlt/)